Your browser doesn't support javascript.
loading
Effects of Hochuekkito combined with pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.
Hamada, Hironobu; Sekikawa, Kiyokazu; Murakami, Isao; Aimoto, Kouichi; Kagawa, Kazuyoshi; Sumigawa, Tatsuya; Okusaki, Ken; Dodo, Takefumi; Awaya, Yoshikazu; Watanabe, Masatoshi; Kondo, Keiichi; Ogawa, Takashi; Yamamoto, Hikaru; Hattori, Noboru.
Afiliação
  • Hamada H; Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-8551, Japan.
  • Sekikawa K; Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-8551, Japan.
  • Murakami I; Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-8551, Japan.
  • Aimoto K; Department of Respiratory Medicine, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Hiroshima 739-0041, Japan.
  • Kagawa K; Department of Respiratory Medicine, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Hiroshima 739-0041, Japan.
  • Sumigawa T; Department of Respiratory Medicine, Hiroshima City Medical Association-Administered Hiroshima City Aki Hospital, Hiroshima, Hiroshima 736-0088, Japan.
  • Okusaki K; Department of Respiratory Medicine, Hiroshima City Medical Association-Administered Hiroshima City Aki Hospital, Hiroshima, Hiroshima 736-0088, Japan.
  • Dodo T; Department of Internal Medicine, Mihara Medical Associations Hospital, Mihara, Hiroshima 723-0051, Japan.
  • Awaya Y; Department of Internal Medicine, Mihara Medical Associations Hospital, Mihara, Hiroshima 723-0051, Japan.
  • Watanabe M; Department of Respiratory Medicine, Miyoshi Central Hospital, Miyoshi, Hiroshima 728-8502, Japan.
  • Kondo K; Department of Respiratory Medicine, Miyoshi Central Hospital, Miyoshi, Hiroshima 728-8502, Japan.
  • Ogawa T; Department of Respiratory Medicine, Tadanoumi Hospital, Takehara, Hiroshima 729-2316, Japan.
  • Yamamoto H; Department of Respiratory Medicine, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Hiroshima 739-0041, Japan.
  • Hattori N; Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-8551, Japan.
Exp Ther Med ; 16(6): 5236-5242, 2018 Dec.
Article em En | MEDLINE | ID: mdl-30542479
ABSTRACT
Chronic obstructive pulmonary disease (COPD) has significant systemic effects, such as weight loss, which affects exercise capacity, health-related quality of life (HRQOL) and survival. The traditional herbal medicine, Hochuekkito (TJ-41), improves the nutritional status and decreases systemic inflammation in patients with COPD. However, to date, the additive effect of TJ-41 on pulmonary rehabilitation (PR) in patients with COPD has not been researched comprehensively. The purpose of the present study was to investigate the efficacy and safety of adding TJ-41 to PR for patients with COPD. Thirty-three malnourished patients with COPD were randomly assigned to receive low-intensity exercise with (TJ-41 group) or without (control group) TJ-41 treatment for 12 weeks. The primary outcome was the change in the 6-min walk distance (6MWD). Secondary outcomes included changes in the body composition, peripheral muscle strength, modified Medical Research Council dyspnea score, visual analog scale (VAS) score for dyspnea, VAS score for fatigue and COPD assessment test (CAT) score. After the 12-week treatment, body weight and percent ideal body weight were significantly increased in the TJ-41 group (P<0.05), but not in the control group. After the 12-week treatment, the modified Medical Research Council dyspnea score, VAS score for dyspnea, VAS score for fatigue and total CAT score decreased significantly in the TJ-41 group (all P<0.05), but not in the control group. There were no significant differences in the 6MWD and peripheral muscle strength between baseline and after 12 weeks of treatment in either group. No adverse effects were noted with the use of TJ-41. It was concluded that the addition of TJ-41 to PR may benefit malnourished patients with COPD with respect to dyspnea and HRQOL.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article